Oracle Stock Upgrade Reframes Valuation

Oracle stock upgrade by Oppenheimer refocuses traders on capex guidance, $50B FY2026 spending, $300B OpenAI exposure and EPS scenarios reshaping valuation.

February 25, 2026·2 min read
View all news articles
Flat vector of a server merged with expanding AI circuit to symbolize Oracle stock upgrade, capex strain and OpenAI exposure.

KEY TAKEAWAYS

  • Oppenheimer upgraded Oracle to Outperform with a $185 price target implying about 27% upside.
  • Oracle's capex guidance rose to roughly $50B for fiscal 2026, increasing financing strain.
  • About $300B of $523B remaining performance obligations are tied to OpenAI, highlighting customer concentration risk.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Oracle Corp. (ORCL) drew fresh analyst attention on Feb. 25, 2026, after Oppenheimer upgraded the stock, focusing scrutiny on the company's capital-intensive shift, OpenAI-linked obligations, and earnings per share (EPS) scenarios shaping valuation and investor risk.

Oppenheimer Upgrade and Earnings Outlook

Oppenheimer raised Oracle’s rating to Outperform from Market Perform and set a $185 price target, implying roughly 27.0% upside from recent levels. The firm’s base case assumes a 25.0% reduction in revenue guidance and projects EPS doubling by fiscal 2030. Its bullish scenario envisions EPS roughly tripling by that date. These outcomes depend on Oracle meeting aggressive growth and margin targets.

Cloud Ambitions, Capital Spending, and Risks

Oracle plans to grow cloud-infrastructure revenue from $18.0 billion in fiscal 2026 to $144.0 billion by fiscal 2030, a key driver of the long-term EPS upside modeled by Oppenheimer. Remaining performance obligations (RPO) stood at $523.0 billion as of Nov. 30, 2025, with about $300.0 billion linked to OpenAI, highlighting significant exposure to that customer.

The company’s fiscal 2026 capital-expenditure (capex) guidance rose to roughly $50.0 billion, $15.0 billion above prior expectations, reflecting a step-up in spending. Oracle reported negative free cash flow of $10.0 billion in the second quarter of fiscal 2026. This capital intensity comes amid securities-fraud class actions related to AI-capex disclosures and partner exposure, as well as a Michigan attorney general’s motion seeking review of a DTE Energy approval for power to an Oracle/OpenAI data-center project over concerns about customer subsidies.

Together, the Oppenheimer upgrade, Oracle’s capital plan, and its large customer obligations frame the stock’s risk-reward profile as a balance between long-term EPS potential and near-term execution and financing challenges.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Nvidia Stock Draws Investor Attention on AI

Nvidia Stock Draws Investor Attention on AI

Nvidia stock drew investor focus after a sharp revenue surge as its AI infrastructure leadership drove flows and attention toward hardware suppliers.

Zoox Robotaxi Expansion Moves Into Phoenix, Dallas

Zoox Robotaxi Expansion Moves Into Phoenix, Dallas

Zoox robotaxi expansion adds Phoenix and Dallas and a Scottsdale Fusion Center, widening U.S. testing and sharpening investor focus on AV scaling.

Anthropic Sues DoD Over Supply-Chain Risk

Anthropic Sues DoD Over Supply-Chain Risk

Anthropic sues DoD to block a supply-chain risk designation and raises procurement questions that could complicate Claude access for defense contracts.

Oil Prices Surge After Middle East Strikes

Oil Prices Surge After Middle East Strikes

Oil prices surge after Middle East strikes and Gulf shipping disruptions drove a Brent crude rally that heightened supply and inflation risks for traders.

Live Nation Settlement Reached With DOJ

Live Nation Settlement Reached With DOJ

Live Nation settlement with the DOJ would force divestitures, open Ticketmaster to rivals and impose about $200 million in damages, pressuring fee income.

Hims & Hers Novo Nordisk Partnership Reported

Hims & Hers Novo Nordisk Partnership Reported

Reports say Hims & Hers Novo Nordisk partnership would let Hims sell Wegovy and Ozempic via telehealth and could alter revenue mix and positioning.